Concepedia

Natalie Zarabi

NZ

4

Publications

77

Citations

4

H-Index

2015

Active since

Affiliations

MSD (Sweden)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Erasmus MC Cancer Institute

Natalie Zarabi is an author at MSD (Sweden) specializing in health economics, public health, and preventive medicine.

ORCID

Top concepts

Publications per year

2015–2023

4

Publications

4

Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy

K. Patterson, Vimalanand S. Prabhu, Ruifeng Xu et al. · European Urology Oncology · 2018 · 27 citations · Full text

Cost-Effectiveness of School-Based Prevention of Cannabis Use

Charlotte Deogan, Natalie Zarabi, Nils Stenström et al. · Applied Health Economics and Health Policy · 2015 · 20 citations

, , +9

Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden

Tushar Srivastava, Vimalanand S. Prabhu, Haojie Li et al. · European Urology Oncology · 2018 · 17 citations · Full text

Clinical and economic burden of pneumococcal disease among adults in Sweden: A population-based register study

Natalie Zarabi, Martina Aldvén, Sigrid Sjölander et al. · PLoS ONE · 2023 · 13 citations · Full text

, , +21

Rows per page

1–4 of 4